CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | 331,300 |
| Gross Profit (TTM) | $-21.00M |
| EBITDA | — |
| Operating Margin | -9407.00% |
| Return on Equity | -107.60% |
| Return on Assets | -60.80% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $1.70 |
| Price-to-Book | 1.67 |
| Price-to-Sales (TTM) | 115.92 |
| EV/Revenue | 307.67 |
| EV/EBITDA | 1.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.60% |
| Shares Outstanding | $15.12M |
| Float | $9.60M |
| % Insiders | 26.43% |
| % Institutions | 22.29% |
Volatility is currently expanding
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026.
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September:
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15 th International Conference on Frontotemporal Dementia (ISFTD) in October 2026; full 12-week and initial, 24-week biomarker data to be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in November 2026 Completed two equity financings in June 2026 for aggregate gross proceeds of approximately $20.5 million, extending cash runway through the third quarter of 2027 BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was marked by meaningful progress across both our business and pipeline.
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod's clinical development program.
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as optimal dosing strategies
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRVO and any ticker you trade — then tracks every position and per-strategy win rate.
